GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » Cyclically Adjusted Price-to-FCF

Iovance Biotherapeutics (LTS:0JDK) Cyclically Adjusted Price-to-FCF : (As of Dec. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Iovance Biotherapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Cyclically Adjusted Price-to-FCF Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Iovance Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF falls into.



Iovance Biotherapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Iovance Biotherapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Iovance Biotherapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.202/133.0289*133.0289
=-0.202

Current CPI (Sep. 2024) = 133.0289.

Iovance Biotherapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.172 99.070 -0.231
201503 -0.113 99.621 -0.151
201506 -0.103 100.684 -0.136
201509 -0.083 100.392 -0.110
201512 -0.142 99.792 -0.189
201603 -0.094 100.470 -0.124
201606 -0.074 101.688 -0.097
201609 -0.219 101.861 -0.286
201612 -0.207 101.863 -0.270
201703 -0.315 102.862 -0.407
201706 -0.281 103.349 -0.362
201709 -0.343 104.136 -0.438
201712 -0.287 104.011 -0.367
201803 -0.212 105.290 -0.268
201806 -0.270 106.317 -0.338
201809 -0.299 106.507 -0.373
201812 -0.267 105.998 -0.335
201903 -0.242 107.251 -0.300
201906 -0.285 108.070 -0.351
201909 -0.350 108.329 -0.430
201912 -0.453 108.420 -0.556
202003 -0.521 108.902 -0.636
202006 -0.312 108.767 -0.382
202009 -0.398 109.815 -0.482
202012 -0.586 109.897 -0.709
202103 -0.496 111.754 -0.590
202106 -0.414 114.631 -0.480
202109 -0.433 115.734 -0.498
202112 -0.391 117.630 -0.442
202203 -0.543 121.301 -0.595
202206 -0.523 125.017 -0.557
202209 -0.412 125.227 -0.438
202212 -0.490 125.222 -0.521
202303 -0.494 127.348 -0.516
202306 -0.461 128.729 -0.476
202309 -0.357 129.860 -0.366
202312 -0.342 129.419 -0.352
202403 -0.475 131.776 -0.480
202406 -0.347 132.554 -0.348
202409 -0.202 133.029 -0.202

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Iovance Biotherapeutics  (LTS:0JDK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Iovance Biotherapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines